

11/30/02

JC685 U.S. PTO

Please type a plus sign (+) inside this box → [+]

02-01-02

A

PTO/SB/05 (03-01)
Approved for use through 10/31/2002 OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications
under 37 CFR 1.53(b))

Attorney Docket No.	8837Q
First Inventor	Ronald Dean Cramer
Assignee	The Procter & Gamble Company
Title	Method Of Hydrophilizing Materials
Express Mail Label No.	ET855571684US

APPLICATION ELEMENTS

See MPEP Chapter 600 concerning utility patent application contents.

ADDRESS TO: **Box Patent Application**
Assistant Commissioner for Patents
Washington, D.C. 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification Total Pages [54]
(preferred arrangement set forth below)
 - Descriptive Title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC §113) Total Sheets [1]
4. Oath or Declaration Total pages ☐
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 complete)
 - i. ☐ **DELETION OF INVENTORS**
Signed statement attached deleting inventor(s)
named in the prior application,
see 37 CFR §§1.63(d)(2) and 1.33(b).
5. ☐ Application Data Sheet. See 37 CFR §1.76

6. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies)
 - ii. ☐ Paper
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS


8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. ☐ Nonpublication Request under 35 U.S.C.
122(b)(2)(B)(i). Applicant must attach form
PTO/SB/35 or its equivalent.
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR §1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. _____
Prior application information: Examiner: _____ Group/Art Unit: _____
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number (Insert Customer No. here)
27752

Name (Print/Type)	Jeffrey V. Bamber	Registration No. (Attorney/Agent)	31,148
Signature		Date	January 30, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231

(Revised for P&G use 12/7/01)



FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision

Complete if Known

Application Number

Confirmation Number

Filing Date

January 30, 2002

First Named Inventor

Ronald Dean Cramer

Examiner Name

Group/Art Unit

TOTAL AMOUNT OF PAYMENT \$740.00

Attorney Docket No.

8837Q

METHOD OF PAYMENT (check one)

- ☒ [X] The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-2480

Deposit Account Name The Procter & Gamble Company

- ☒ [X] Charge Any Additional Fee Required Under status. 37 C.F.R. §§1.16 and 1.17

FEE CALCULATION

1. BASIC FILING FEE - Large Entity

Code	(\$)	Fee Description	Fee Paid
101	740	Utility filing fee	[740]
106	330	Design filing fee	[]
108	740	Reissue filing fee	[]
114	160	Provisional filing fee	[]

SUBTOTAL (1) \$740

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE - Large Entity

Total Claims	[11] - 20** =	Extra Claims	[0] x	Fee from Below	[] =	Fee Paid
Independent Claims	[1] - 3** =	[0] x	[]	=	[]	
Multiple Dependent		[]	=	[]		

Independent Claims [1] - 3** = [0] x [] = []

Multiple Dependent [] = []

** or number previously paid, if greater; For Reissues, see below

Code	(\$)	Fee Description
103	18	Claims in excess of 20
102	84	Independent claims in excess of 3
104	280	Multiple dependent claim, if not paid
109	84	**Reissue independent claims over original patent
110	18	**Reissue claims in excess of 20 & over original patent

SUBTOTAL (2) (\$)[]

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Code	(\$)	Fee Description	Fee Paid
105	130	Surcharge-late filing fee or oath	[]
127	50	Surcharge-late provisional filing fee or cover sheet	[]
139	130	Non-English specification	[]
147	2,520	For filing a request for <i>ex parte</i> reexamination	[]
112	920*	Requesting publication of SIR prior to Examiner's action	[]
113	1,840*	Requesting publication of SIR after Examiner's action	[]
115	110	Extension for reply within 1 st month	[]
116	400	Extension for reply within 2 nd month	[]
117	920	Extension for reply within 3 rd month	[]
118	1,440	Extension for reply within 4 th month	[]
128	1,960	Extension for reply within 5 th month	[]
119	320	Notice of Appeal	[]
120	320	Filing a brief in support of an appeal	[]
121	280	Request for oral hearing	[]
138	1,510	Petition to institute a public use proceeding	[]
140	110	Petition to revive - unavoidable	[]
141	1,280	Petition to revive - unintentional	[]
142	1,280	Utility issue fee (or reissue)	[]
143	460	Design issue fee	[]
122	130	Petitions to the Commissioner	[]
123	50	Petitions related to provisional applications (37 C.F.R. 1.17(q))	[]
126	180	Submission of Information Disclosure Statement	[]
146	740	Filing a submission after final rejection (37 CFR § 1.129(a))	[]
149	740	For each additional invention to be examined (37 CFR §1.129(b))	[]
179	740	Request for Continued Examination (RCE)	[]
169	900	Request for expedited examination of a design application	[]
091	1280	Acceptance of unintentionally delayed claim for priority under 35 U.S.C. 119, 120, 121, or 365 (a) or (c)	[]
		Other fee (specify) _____	[]
		Other fee (specify) _____	[]

* Reduced by Basic Filing Fee Paid SUBTOTAL(3) (\$)[]

SUBMITTED BY

Name (Print/Type)	Jeffrey V. Bamber	Registration No. (Attorney/Agent)	31,148	Complete (if applicable)	
Signature				Telephone	(513) 627-4597
				Date	January 30, 2002

WARNING: Information on this form is to be made public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

